Arno Therapeutics
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resi… Read more
Arno Therapeutics (ARNI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2016: 0.200x
Based on the latest financial reports, Arno Therapeutics (ARNI) has a cash flow conversion efficiency ratio of 0.200x as of September 2016.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.14 Million) by net assets ($-5.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Arno Therapeutics - Cash Flow Conversion Efficiency Trend (2012–2015)
This chart illustrates how Arno Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Arno Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arno Therapeutics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RENALYTIX SP.ADS/2
F:2O9A
|
N/A |
|
Orchard Funding Group PLC
LSE:ORCH
|
-0.043x |
|
Nasdaq Global Travel and Leisur
STU:A4E1
|
N/A |
|
Nicolas Miguet et Associes SA
PA:MLNMA
|
N/A |
|
Spirits Time International Inc
PINK:SRSG
|
0.007x |
|
Amper SA
MU:APR
|
N/A |
|
Mix1 Life Inc
PINK:MIXX
|
-0.005x |
|
ECOFIN US REN.IN. DL -01
F:9FV
|
N/A |
Annual Cash Flow Conversion Efficiency for Arno Therapeutics (2012–2015)
The table below shows the annual cash flow conversion efficiency of Arno Therapeutics from 2012 to 2015.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2015-12-31 | $-8.62 Million | $-9.97 Million | 1.156x | +118.19% |
| 2014-12-31 | $2.96 Million | $-18.81 Million | -6.354x | -658.61% |
| 2013-12-31 | $-12.52 Million | $-14.24 Million | 1.138x | +37.27% |
| 2012-12-31 | $-11.37 Million | $-9.42 Million | 0.829x | -- |